Prevention & Lipids
PCSK9 inhibitors
PCSK9i efficacy, outcomes, and cost-effectiveness
Unknown pathwayAlso known as: PCSK9i, evolocumab, alirocumab
221
Clinical questions
13
Evidence-backed
0
Claims analyzed
Prevention & Lipids
PCSK9i efficacy, outcomes, and cost-effectiveness
Synthesized from 13 evidence-backed clinical questions linked to this topic — 5 supporting the intervention, 3 against the intervention.
Does evolocumab vs placebo affect 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization) in Atherosclerotic Cardiovascular Disease?
Moderate Certainty+ Favors benefitevolocumab vs placebo · 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization)
1 studies (27,564 patients, 1 RCTs) provide moderate-certainty evidence for benefit of evolocumab for 5-point MACE (CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) in Atherosclerotic Cardiovascular Disease.
Does evolocumab vs placebo affect 3-point MACE (CV death, non-fatal MI, non-fatal stroke) in Atherosclerotic Cardiovascular Disease?
Moderate Certainty+ Favors benefitevolocumab vs placebo · 3-point MACE (CV death, non-fatal MI, non-fatal stroke)
1 studies (27,564 patients, 1 RCTs) provide moderate-certainty evidence for benefit of evolocumab for Key secondary 3-point MACE (CV death, MI, or stroke) in Atherosclerotic Cardiovascular Disease.
Does evolocumab vs placebo affect Cardiovascular Mortality in Atherosclerotic Cardiovascular Disease?
Moderate Certainty≈ Likely no clinically meaningful effectevolocumab vs placebo · Cardiovascular Mortality
1 studies (27,564 patients, 1 RCTs) provide moderate-certainty evidence showing no clinically meaningful effect of evolocumab for Cardiovascular mortality in Atherosclerotic Cardiovascular Disease.
No claims extracted for this topic
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does evolocumab vs placebo affect 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization) in Atherosclerotic Cardiovascular Disease?
Moderate Certainty+ Favors benefitevolocumab vs placebo · 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization)
Does evolocumab vs placebo affect 3-point MACE (CV death, non-fatal MI, non-fatal stroke) in Atherosclerotic Cardiovascular Disease?
Moderate Certainty+ Favors benefitThe Molecular and Clinical Impact of Atorvastatin Exposure on Paclitaxel Neurotoxicity in Sensory Neurons and Cancer Patients
Basic & Clinical Pharmacology & Toxicology — Simonsen E — Mar 2025
Statin Therapy Helps to Control Blood Pressure Levels in Hypertensive Dyslipidemic Patients
Renal Failure — Kanbay M — Jan 2005
Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability‐Free Survival in Older People
Journal of the American Heart Association — Zoungas S — Nov 2024
Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction
JAMA — Räber L — Apr 2022
Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention ― A Meta-Analysis of 12 Randomized Trials ―
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
PCSK9 inhibitors (also known as PCSK9i, evolocumab, alirocumab). PCSK9i efficacy, outcomes, and cost-effectiveness
Synapse tracks 4 specific clinical questions in PCSK9 inhibitors, each synthesized independently from its own trial evidence. They include: "Does evolocumab vs placebo affect 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization) in Atherosclerotic Cardiovascular Disease?"; "Does evolocumab vs placebo affect 3-point MACE (CV death, non-fatal MI, non-fatal stroke) in Atherosclerotic Cardiovascular Disease?"; "Does alirocumab vs statin improve outcomes in Acute Coronary Syndrome?"; "Does evolocumab vs placebo affect Cardiovascular Mortality in Atherosclerotic Cardiovascular Disease?".
As of 2026-08-15, the scientific consensus on PCSK9 inhibitors is unknown. No claims extracted for this topic
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/pcsk9-inhibitors.
Deterministic synthesis from Synapse's enriched corpus — 120 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every PCSK9 inhibitors paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search PCSK9 inhibitors papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
evolocumab vs placebo · 3-point MACE (CV death, non-fatal MI, non-fatal stroke)
Circulation Journal — Wang S — Apr 2019